Influenza A Virus Pool (Control Antigen) 2112

$75.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Cost-effective due to standardized reagents
Lyophilized antigens, control antigens as well as positive and negative control sera simplify storage
Suitable screening test to identify acute infections
Compensation of seroprevalences allow high specificity

SKU: 2112 Category: Infectious disease proteins Tags: antigen, Influenza Virus, protein

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Influenza A immunoglobulins
species reactivity	Influenza A
applications	CFT (Complement fixation test)
assay type	qualitative
available size	1 mL

Influenza A Virus Pool (Control Antigen) 2112

kit
Research area Infectious Disease
Storage Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Associated products Coxiella burnetii Phase 2 IgG Control Serum (BC1312G) Coxiella burnetii Phase 2 IgM Control Serum (BC1312M) Coxiella burnetii IgA Phase I ELISA Kit (ESR1311A) Coxiella burnetii IgG Phase I ELISA Kit (ESR1311G) Coxiella burnetii IgG Phase II ELISA Kit (ESR1312G) Coxiella burnetii IgM Phase II ELISA Kit (ESR1312M)

target relevance
Influenza Virus
Description Virus that causes influenza (flu)
Structure Influenza viruses are enveloped, negative-sense, single-stranded RNA viruses belonging to the Orthomyxoviridae family. The viral genome is segmented into multiple RNA molecules, allowing genetic reassortment between different strains. Influenza A and B viruses are the primary causes of seasonal influenza in humans, while Influenza A viruses also infect a wide range of animal species including birds, pigs, horses, and marine mammals. The viral envelope contains the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are responsible for viral attachment, entry, and release from host cells. Influenza viruses are characterized by a high mutation rate, resulting in antigenic drift and the emergence of new variants. Periodically, reassortment events between different influenza strains can result in antigenic shift, leading to the emergence of pandemic viruses.
Diagnosis The diagnosis of influenza is performed by the detection of viral RNA, viral antigens, or influenza-specific antibodies. Molecular methods such as reverse transcription polymerase chain reaction (RT-PCR) are considered the gold standard for the detection and differentiation of influenza virus types and subtypes. Rapid influenza diagnostic tests (RIDTs) detect viral antigens and provide results within minutes but generally have lower sensitivity than molecular methods. Serological assays including ELISA and hemagglutination inhibition tests may be used to determine previous exposure, monitor immune responses, or support epidemiological investigations. Influenza-specific IgM antibodies typically appear during the acute phase of infection, while IgG antibodies develop later and may persist for years, providing varying degrees of immunity against related viral strains.
Symptoms Influenza viruses are highly contagious respiratory pathogens that spread primarily through respiratory droplets and aerosols generated by infected individuals. Following an incubation period of approximately one to four days, influenza typically presents with abrupt onset of fever, chills, headache, myalgia, fatigue, sore throat, and dry cough. Additional symptoms may include nasal congestion, runny nose, and loss of appetite. Although most infections are self-limiting, severe disease can occur in young children, elderly individuals, pregnant women, and immunocompromised patients. Complications include viral pneumonia, secondary bacterial pneumonia, myocarditis, encephalitis, and acute respiratory distress syndrome (ARDS). Seasonal influenza is responsible for substantial morbidity and mortality worldwide, and periodic pandemics caused by novel influenza A strains can result in widespread outbreaks with significant public health impact.

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Influenza A Virus Pool (Control Antigen) 2112?

The Influenza A Virus Pool (Control Antigen) 2112 should be stored at -65°C and freeze/thaw cycles should be avoided. It is also recommended to sonicate the antigen before use.

For which assay is the Influenza A Virus Pool (Control Antigen) 2112 primarily designed?

This control antigen is suitable for qualitative Complement Fixation Test (CFT) applications to detect Influenza A immunoglobulins.

Which species does the Influenza A Virus Pool (Control Antigen) 2112 target?

The antigen targets Influenza A virus and is reactive with Influenza A immunoglobulins.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.